Compound ID | 567
ABI200
Class: Engineered bacteriophage endolysin
| Spectrum of activity: | Gram-negative |
| Details of activity: | A fusion protein with mutiple lytic domains to lyse Gram positives. Designed to overcome multidrug resistant Gram-positive bacterial strains in veterinary medicine. |
| Institute where first reported: | AdRem Biotech, USA |
| Year first mentioned: | 2009 |
| Highest developmental phase: | Preclinical |
| Development status: | Inactive |
| External links: | |
| Citation: |
AntibioticDB is supported by GARDP.
If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions
The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.